Meghan D Morris1, Anna Bates2, Erin Andrew3, Judith Hahn4, Kimberly Page5, Lisa Maher2. 1. University of California at San Francisco, San Francisco, CA, USA. Electronic address: Meghan.Morris@ucsf.edu. 2. The Kirby Institute, UNSW Australia, Sydney, Australia. 3. San Francisco Department of Public Health, San Francisco, CA, USA. 4. University of California at San Francisco, San Francisco, CA, USA. 5. University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Abstract
BACKGROUND: Studies have shown intimate injection partners engage in higher rates of syringe and injecting equipment sharing. We examined the drug use context and development of injection drug use behaviors within intimate injection partnerships. METHODS: In-depth interviews (n=18) were conducted with both members of nine injecting partnerships in Sydney, Australia. Content analysis identified key domains related to the reasons for injecting with a primary injection partner and development of drug injection patterns. MAIN FINDINGS: Most partnerships (n=5) were also sexual; three were blood-relatives and one a friend dyad. The main drug injected was heroin (66%) with high rates of recent sharing behaviors (88%) reported within dyads. Injecting within a primary injection partnership provided perceived protection against overdose events, helped reduce stress, increased control over when, where, and how drugs were used, and promoted the development of an injecting pattern where responsibilities could be shared. Unique to injecting within primary injection partnerships was the social connection and companionship resulted in a feeling of fulfillment while also blinding one from recognizing risky behavior. CONCLUSIONS: Findings illuminated the tension between protection and risks within primary injection partnerships. Primary injection partnerships provide a potential platform to expand risk reduction strategies.
BACKGROUND: Studies have shown intimate injection partners engage in higher rates of syringe and injecting equipment sharing. We examined the drug use context and development of injection drug use behaviors within intimate injection partnerships. METHODS: In-depth interviews (n=18) were conducted with both members of nine injecting partnerships in Sydney, Australia. Content analysis identified key domains related to the reasons for injecting with a primary injection partner and development of drug injection patterns. MAIN FINDINGS: Most partnerships (n=5) were also sexual; three were blood-relatives and one a friend dyad. The main drug injected was heroin (66%) with high rates of recent sharing behaviors (88%) reported within dyads. Injecting within a primary injection partnership provided perceived protection against overdose events, helped reduce stress, increased control over when, where, and how drugs were used, and promoted the development of an injecting pattern where responsibilities could be shared. Unique to injecting within primary injection partnerships was the social connection and companionship resulted in a feeling of fulfillment while also blinding one from recognizing risky behavior. CONCLUSIONS: Findings illuminated the tension between protection and risks within primary injection partnerships. Primary injection partnerships provide a potential platform to expand risk reduction strategies.
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: Daniel Tracy; Judith A Hahn; Crystal Fuller Lewis; Jennifer Evans; Alya Briceño; Meghan D Morris; Paula J Lum; Kimberly Page Journal: BMJ Open Date: 2014-05-29 Impact factor: 2.692
Authors: Meghan D Morris; Martha E Montgomery; Alya Briceno; Jennifer L Evans; Erin V W Andrew; Kimberly Page; Judith A Hahn Journal: Subst Use Misuse Date: 2017-12-29 Impact factor: 2.164
Authors: A Esmaeili; A Mirzazadeh; G M Carter; A Esmaeili; B Hajarizadeh; H S Sacks; K A Page Journal: J Viral Hepat Date: 2016-10-28 Impact factor: 3.728
Authors: Andrew Scheibe; Katherine Young; Lorraine Moses; Rudolph L Basson; Anna Versfeld; C Wendy Spearman; Mark W Sonderup; Nishi Prabdial-Sing; Jack Manamela; Adrian J Puren; Kevin Rebe; Harry Hausler Journal: Harm Reduct J Date: 2019-04-11
Authors: Eshan U Patel; Sunil S Solomon; Gregory M Lucas; Allison M McFall; Cecília Tomori; Aylur K Srikrishnan; Muniratnam S Kumar; Oliver Laeyendecker; David D Celentano; David L Thomas; Thomas C Quinn; Shruti H Mehta Journal: Int J Drug Policy Date: 2021-07-08